Sign in Subscribe

Jitesh Rana, MD

I am a medical affairs and patient safety professional. I have successfully led patient safety from phase 1-4, and the launched new products in market. I am generally known to remain calm when others are freaking out.

Jitesh Rana, MD
MC2R Antagonism vs. Upstream Modulation: Determining the Biochemical Ceiling in Refractory CAH

Uncategorized

MC2R Antagonism vs. Upstream Modulation: Determining the Biochemical Ceiling in Refractory CAH

Phase 2 data indicates Atumelnant establishes a 'medical adrenalectomy' effect, significantly outperforming forthcoming standard of care in androgen suppression. See Disclaimer below * Unmet Medical Need and Epidemiology Congenital Adrenal Hyperplasia (CAH) represents a spectrum of enzymatic defects, predominantly 21-hydroxylase deficiency, leading to cortisol insufficiency and androgen excess.

By Jitesh Rana, MD
Redefining the Standard of Care in Recurrent Glioblastoma: ANKTIVA Positioned to Disrupt the Cytotoxic Paradigm in Neuro-Oncology via Outpatient 'Chemo-Free' Delivery

Oncology

Redefining the Standard of Care in Recurrent Glioblastoma: ANKTIVA Positioned to Disrupt the Cytotoxic Paradigm in Neuro-Oncology via Outpatient 'Chemo-Free' Delivery

Interim QUILT-3.078 data reveals a mechanistic pivot from myelosuppressive standards to immune-restorative therapy, shattering historical survival ceilings. See Disclaimer below * Glioblastoma (GBM) remains one of the most lethal malignancies, with a 5-year survival rate of < 7%. The recurrent setting (rGBM) represents a catastrophic failure of

By Jitesh Rana, MD
Clinical Profile Assessment: Dersimelagon (MT-7117) Efficacy Parity and Safety Trade-offs in Porphyria Management

Uncategorized

Clinical Profile Assessment: Dersimelagon (MT-7117) Efficacy Parity and Safety Trade-offs in Porphyria Management

Phase 3 INSPIRE data demonstrates functional non-inferiority to standard of care afamelanotide, though GI toxicity profile necessitates rigorous titration protocols. See Disclaimer below * Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) represent a debilitating spectrum of photodermatoses characterized by acute, excruciating phototoxicity. While the prevalence is rare (estimated at

By Jitesh Rana, MD
Fc-Silent Engineering Validated: Tegoprubart Demonstrates Functional Superiority Over Tacrolimus Despite Higher Acute Rejection Rates

Uncategorized

Fc-Silent Engineering Validated: Tegoprubart Demonstrates Functional Superiority Over Tacrolimus Despite Higher Acute Rejection Rates

Tegoprubart (AT-1501) trades acceptable, reversible rejection for superior eGFR preservation and a pristine metabolic safety profile. See Disclaimer below * Addressing the 'Toxic Compromise' Kidney transplantation remains the only curative therapy for End-Stage Renal Disease (ESRD), yet the clinical standard of care has stagnated for two decades.

By Jitesh Rana, MD
Ulixacaltamide’s Path to Standard-of-Care Status in Essential Tremor: Clinical Precision and Commercial Realities

Uncategorized

Ulixacaltamide’s Path to Standard-of-Care Status in Essential Tremor: Clinical Precision and Commercial Realities

T-type calcium channel inhibition decouples tremor reduction from systemic toxicity. See Disclaimer below * The current pharmacopoeia for Essential Tremor (ET) relies heavily on systemic blunting agents—beta-blockers and barbiturates—that reduce tremor amplitude at the cost of significant physiological depression. Ulixacaltamide (PRAX-944) represents a fundamental divergence from

By Jitesh Rana, MD
The Biological Pivot: How Rezpegaldesleukin is Engineering a "Safety-First" Bifurcation in the $4 Billion Alopecia Market

Uncategorized

The Biological Pivot: How Rezpegaldesleukin is Engineering a "Safety-First" Bifurcation in the $4 Billion Alopecia Market

The Phase 2b REZOLVE-AA data is statistically messy but strategically pristine. By decoupling efficacy from toxicity, Nektar Therapeutics has identified the precise wedge needed to break the JAK inhibitor monopoly. See Disclaimer below * The Statistical Mirage and the True Signal In the high-stakes theater of immunology drug development,

By Jitesh Rana, MD
See all